Clinical management of infections caused by multidrug-resistant Enterobacteriaceae

Area of Science:

• Microbiology
• Infectious Diseases
• Pharmacology

Background:

• The rise of multidrug-resistant Enterobacteriaceae, particularly those producing extended-spectrum β-lactamases (ESBLs), plasmid-mediated AmpC enzymes, and carbapenemases, presents a significant global challenge.
• These resistant strains often exhibit co-resistance to other common antibiotics like fluoroquinolones and aminoglycosides, severely limiting therapeutic options.

Purpose of the Study:

• To review current treatment strategies for infections caused by multidrug-resistant Enterobacteriaceae.
• To highlight the increasing use of older antibiotics and the importance of evidence-based therapeutic approaches.

Main Methods:

• Review of in vitro data, animal studies, and observational studies.
• Analysis of current clinical recommendations and emerging treatment trends for resistant Enterobacteriaceae infections.

Main Results:

• Carbapenems remain the preferred agents for ESBL and AmpC producers, but alternatives are emerging for specific infections.
• Combined therapy demonstrates superiority over monotherapy for carbapenemase-producing Enterobacteriaceae infections.
• Pharmacokinetic/pharmacodynamic (PK/PD) optimization is vital for managing infections with borderline minimum inhibitory concentrations.

Conclusions:

• Multidrug-resistant Enterobacteriaceae infections are associated with increased morbidity and mortality.
• The increasing prevalence and spread of resistance necessitate a complex public health response.
• Strategic use of older antibiotics, combined therapies, and optimized dosing are critical for managing these challenging infections.